FTH · Faeth Therapeutics, Inc.
$29.74
+1.67 (+5.95%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 4, 2026
The latest filing no longer states the doubt (first flagged May 15, 2026).
View the 10-Q filed Aug 4, 2026Market Cap
$723.53M
Shares
25.84M
Volume · Sep 30
356.52K
Avg daily vol (3M)
338.77K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.74
Open$28.49
Day$27.67–30.18
52W close$7.89–40.05
Avg vol 30d400K
Short int1.3M · 5.1% float · 4.4d
Short vol37%
Last earningsAug 5, 2025
DataFeb 2021–Sep 2026
Filing10-Q · Aug 4
Up next
filed Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+193.9%
Trailing year
Short interest
5.1%
Latest settlement · 4.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+25%
above
Price vs 50-day avg
−7%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
68%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−3%
trailing
YTD return
+179%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $32 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
+50% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.10% of float · ▲ +20.1% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
45 holders — near 1-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
EPS growth
+30%
Y/Y
Free cash flow
$-20.5M
Balance sheet
$16.0M
net cash
Quant / Vol
risk profile
Volatility
223%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
9.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+25%
Bullish
Price vs 50-day avg
−7%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
68%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $32 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
+50% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.10% of float · ▲ +20.1% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
45 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $8
Now $30 · 68%
Range high $40
vs 200-day avg +25%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FTH
this stock
Faeth Therapeutics, Inc.
|
$723.53M | +178.7% | — | — | 5.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FTH | -5.7% | -13.8% | -2.6% | -9.3% | +178.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -5.1% | -13.9% | -14.8% | -8.7% | +166.9% |